Straits Times Index
3,296.89 +4.20 (+0.13%) S&P 500
5,058.73 +40.34 (+0.80%) Dow
38,172.06 +268.77 (+0.71%) Nasdaq
15,825.02 +219.54 (+1.41%) Bitcoin USD
59,328.91 +1,915.08 (+3.34%) CMC Crypto 200
1,274.16 +3.42 (+0.27%)
Bristol-Myers Squibb Company (BMY)
| Previous close | 44.21 |
| Open | 44.36 |
| Bid | 43.76 x 800 |
| Ask | 43.77 x 800 |
| Day's range | 43.33 - 44.42 |
| 52-week range | 43.33 - 69.10 |
| Volume | |
| Avg. volume | 15,909,093 |
| Market cap | 88.582B |
| Beta (5Y monthly) | 0.39 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | 2.40 (5.43%) |
| Ex-dividend date | 04 Apr 2024 |
| 1y target est | N/A |
- GlobeNewswire
Editas Medicine and Bristol Myers Squibb Extend Alpha-Beta T Cell Collaboration
Two-year extension for research and development of alpha-beta T cell medicines for the treatment of cancer and autoimmune diseasesCAMBRIDGE, Mass., May 01, 2024 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage gene editing company, today announced a two-year extension to the collaboration with Bristol Myers Squibb (NYSE: BMY) under which the parties may research, develop, and commercialize autologous and allogeneic alpha-beta T cell medicines for the treatment of cancer
- PR Newswire
Repertoire® Immune Medicines and Bristol Myers Squibb Announce Multi-Year Strategic Collaboration to Develop Tolerizing Vaccines for Autoimmune Diseases
Repertoire® Immune Medicines, a biotechnology company pioneering the discovery and development of programmable T cell targeted immune medicines, announced today that it has entered a multi-year strategic collaboration with Bristol Myers Squibb (NYSE: BMY) to develop tolerizing vaccines for up to three autoimmune diseases. The collaboration aims to develop efficacious, selective, and durable treatments for patients suffering from autoimmune disease by resetting the immune system.
- Business Wire
CHMP Adopts Positive Opinion Recommending Approval of Bristol Myers Squibb’s Opdivo® (nivolumab) in Combination with Cisplatin and Gemcitabine for the First-Line Treatment of Adult Patients with Unresectable or Metastatic Urothelial Carcinoma
PRINCETON, N.J., April 26, 2024--CHMP Adopts Positive Opinion Recommending Approval of Bristol Myers Squibb’s Opdivo® (nivolumab) in Combination with Cisplatin and Gemcitabine....
